Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

35.83 +0.06 (+0.17%)

Streaming Delayed Price Updated: 10:44 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗

January 26, 2026

Via Chartmill

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Via MarketMinute

Topics Artificial Intelligence Death

Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗

December 25, 2025

Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗

December 02, 2025

Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation.

Via Chartmill

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗

October 30, 2025

Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗

October 14, 2025

Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗

October 08, 2025

Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗

August 13, 2025

Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential.

Via Chartmill

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts ↗

February 25, 2025

Via Benzinga

Veracyte (VCYT) Q2 Revenue Jumps 14% ↗

August 07, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗

July 26, 2025

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals ↗

July 21, 2025

VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors.

Via Chartmill

Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet ↗

June 21, 2025

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems ↗

June 07, 2025

Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology ↗

May 28, 2025

VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth...

Via Chartmill

Breaking Down Veracyte: 7 Analysts Share Their Views ↗

May 08, 2025

Via Benzinga

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch ↗

May 02, 2025

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch

Via Chartmill

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms ↗

April 26, 2025

ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.

Via Benzinga

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability. ↗

April 12, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable. ↗

March 22, 2025

NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

5 Analysts Assess Veracyte: What You Need To Know ↗

March 20, 2025

Via Benzinga

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗

March 12, 2025

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank. ↗

February 27, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive ↗

February 25, 2025

Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.